文献速递临床试验与 GCP基础与转化研究

远程医疗递送的失眠认知行为疗法治疗酒精使用障碍:随机对照试验研究方案

Telemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-01-20

这是一项单中心随机对照试验,计划纳入150名同时符合酒精使用障碍(AUD)和慢性失眠诊断的成人,按1:1随机分配接受6次远程医疗递送的失眠认知行为疗法(CBT-TM)或睡眠卫生教育(SHE-TM)。主要临床结局包括治疗后失眠严重指数、多维疲劳量表一般疲劳子量表评分及完全戒酒天数百分比,主要睡眠机制终点为夜间多导睡眠图衍生的EEG delta活动。

要点

  • 试验比较CBT-TM与SHE-TM对AUD合并失眠患者的失眠、日间症状及饮酒结局的影响。
  • 评估治疗对睡眠稳态机制(EEG delta活动)的作用及其与临床结局的关联。
  • 计划纳入150名成人,1:1随机,治疗后及3、6、12个月随访评估。

核心结论

  • 该试验将提供关于针对失眠的治疗能否改善寻求治疗的AUD成人治疗结局的临床相关信息。
  • 研究还将就基于证据的非药物治疗对失眠对该人群睡眠功能障碍候选机制——睡眠稳态的影响提供新的科学见解。

研究设计与样本

  • 单中心随机对照试验,计划纳入150名同时符合AUD和慢性失眠标准的成人。
  • 参与者按1:1随机分配接受6次远程医疗递送的失眠认知行为疗法(CBT-TM)或睡眠卫生教育(SHE-TM)。
  • 临床评估在治疗前、治疗后及治疗后3、6、12个月进行;治疗前后进行夜间多导睡眠图检查。

关键数值与推荐

  • 主要临床结局包括治疗后失眠严重指数评分、多维疲劳量表一般疲劳子量表评分及访谈式时间线回溯法评估的完全戒酒天数百分比。
  • 主要睡眠机制终点为夜间多导睡眠图衍生的EEG delta活动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improves insomnia and daytime functioning in adults with AUD and insomnia. The impact of CBT for insomnia on relapse, however, is unclear. This trial will compare telemedicine-delivered CBT for insomnia (CBT-TM) with sleep hygiene education (SHE-TM) on improving insomnia/sleep, daytime symptom, and drinking outcomes in treatment-seeking AUD adults with insomnia. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. METHODS: This is a single-site randomized controlled trial with planned enrollment of 150 adults meeting criteria for both AUD and chronic insomnia. Eligible participants will be randomized 1:1 to 6 sessions of telemedicine-delivered Cognitive Behavioral Therapy for Insomnia (CBT-TM) or Sleep Hygiene Education (SHE-TM) with clinical assessments conducted at pre-treatment, post- treatment, and at 3, 6, and 12 months post-treatment. Overnight polysomnography will be conducted before and after treatment. Primary clinical outcomes will include post-treatment scores on the Insomnia Severity Index and the General Fatigue subscale of the Multidisciplinary Fatigue Inventory, and the percent of days abstinent (PDA) on the interview-administered Time Line Follow Back. EEG delta activity, derived from overnight polysomnography, will be the primary endpoint to assess the sleep homeostasis mechanism. DISCUSSION: This adequately powered randomized controlled trial will provide clinically relevant information about whether targeting insomnia is effective for improving treatment outcomes among treatment-seeking adults with AUD. Additionally, the study will offer new scientific insights on the impact of an evidence-based non-medication treatment for insomnia on a candidate mechanism of sleep dysfunction in this population - sleep homeostasis. TRIAL REGISTRATION: CClinicalTrials.gov NCT # 04457674 . Registered on 07 July 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arnedt JT, Cardoni ME, Conroy DA, et al. Telemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial. Trials. 2022. PMID: 35057834. doi:10.1186/s13063-021-05898-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。